Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C L Vogel

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Investigational New Drugs|September 1, 1988
Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancerL Barreras, C L Vogel, G Koch, et al.
Cancer|September 15, 1987
Response to tamoxifen in estrogen receptor-poor metastatic breast cancerC L Vogel, D R East, W Voigt, et al.
Investigational New Drugs|April 1, 1988
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trialE B Cox, C L Vogel, J T Carpenter, et al.
Cancer|December 15, 1995
Phase II study of oral etoposide for patients with advanced breast cancerD M Atienza, C L Vogel, B Trock, et al.
Cancer Treatment Reports|July 1, 1976
Phase I trial of dianhydrogalactitol administered Iv in a weekly scheduleC L Vogel, E F Winton, M R Moore, et al.
The Oncologist|June 26, 2001
Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II studyH S Hochster, C L Vogel, S L Burman, et al.
Cancer|June 1, 1988
Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literatureE Davila, C L Vogel, D East, et al.
Cancer Treatment Reports|December 1, 1978
Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapyJ M Denefrio, D R East, M B Troner, et al.
Cancer Treatment Reports|October 1, 1980
Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)C L Vogel, J M Denefrio, D C Padgett, et al.
Cancer|July 1, 1992
Survival after first recurrence of breast cancer. The Miami experienceC L Vogel, S Azevedo, S Hilsenbeck, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Investigational New Drugs|September 1, 1988
Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancerL Barreras, C L Vogel, G Koch, et al.
Cancer|September 15, 1987
Response to tamoxifen in estrogen receptor-poor metastatic breast cancerC L Vogel, D R East, W Voigt, et al.
Investigational New Drugs|April 1, 1988
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trialE B Cox, C L Vogel, J T Carpenter, et al.
Cancer|December 15, 1995
Phase II study of oral etoposide for patients with advanced breast cancerD M Atienza, C L Vogel, B Trock, et al.
Cancer Treatment Reports|July 1, 1976
Phase I trial of dianhydrogalactitol administered Iv in a weekly scheduleC L Vogel, E F Winton, M R Moore, et al.
The Oncologist|June 26, 2001
Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II studyH S Hochster, C L Vogel, S L Burman, et al.
Cancer|June 1, 1988
Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literatureE Davila, C L Vogel, D East, et al.
Cancer Treatment Reports|December 1, 1978
Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapyJ M Denefrio, D R East, M B Troner, et al.
Cancer Treatment Reports|October 1, 1980
Phase I clinical trial of weekly iv 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY)C L Vogel, J M Denefrio, D C Padgett, et al.
Cancer|July 1, 1992
Survival after first recurrence of breast cancer. The Miami experienceC L Vogel, S Azevedo, S Hilsenbeck, et al.
Pageof 6